Pharmabiz2h
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
FiercePharma13h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Anixa Shares Rise on Plans for Phase 2 Study of Breast Cancer Vaccine
Shares in Anixa Biosciences rose after the company outlined plans for a Phase 2 study of its breast cancer vaccine. Shares were recently up 5% at $3.39.
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for ...
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ...
The Pharma Letter20h
Two regulatory approvals for Astellas
In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.